Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of retinal diseases. The company focuses on small-molecule drugs designed to preserve, slow down, or restore vision loss in patients with inherited and age-related degenerative retinal diseases. Its lead product, KIO-301, is a photoswitch small molecule intended to restore vision in patients with retinitis pigmentosa, for which it has received Orphan Drug Designation from the FDA and Orphan Medicinal Product Designation from the European Medicines Agency. KIO-301 was acquired through the Bayon Therapeutics transaction and is currently in a Phase 2 clinical trial. The company is also developing KIO-104, a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase formulated for intravitreal delivery, for the treatment of retinal inflammatory diseases including Diabetic Macular Edema and Posterior Non-Infectious Uveitis. KIO-104 was acquired through the Panoptes Pharma acquisition and is in a Phase 2 trial. Additionally, Kiora is developing KIO-101, an ophthalmic topical eye drop formulation of the same active compound as KIO-104, for the ocular manifestations of autoimmune diseases such as rheumatoid arthritis. The company serves patients with retinal diseases in the United States and Europe, partnering with Théa Open Innovation for the development of KIO-301.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage kiorapharma.com
Sector Healthcare IR page ir.kiorapharma.com
Tags
retinal diseases, retinitis pigmentosa, diabetic macular edema, uveitis, small molecules, ion channel modulators, dhodh inhibitors, ophthalmology, clinical-stage, orphan drugs, KIO-301, KIO-104, KIO-101, B-203, PP-001, Bayon Therapeutics, Panoptes Pharma, Théa Open Innovation, Laboratories Théa
Press page —

Metrics

Valuation  
Market cap $ 11.326M
Market cap (USD) $ 11.326M
P/E -0.92
PEG —
P/BV 0.74
P/S 0.71
P/OCF -1.45
P/FCF -1.12
Dividend yield —
Turnover / mcap —
Returns  
ROE -51.7%
ROI -141.9%
ROIC -126.1%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 17
Quality score -46.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 0 16.02M — — 0 12.059K 2.686M 1.653M 407.518K 669.259K — —
Net profit -10.835M 3.595M -12.514M -13.584M -16.395M -8.092M -7.097M -10.811M -13.218M -13.343M -8.388M -1.552M
Free cash flow -10.072M 8.553M -9.557M -10.428M -10.952M -7.337M — -10.865M -6.506M — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 1.97 3.3 0.52 3.43 1.51 4.93 10 0.46 1.07 1.63 2.72 —
Price performance 12m -0.4 5.32 -0.85 1.27 -0.69 -0.51 20.55 -0.57 -0.34 -0.4 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — — 0.00 601,197 1.52M
↳ YoY growth +153.3%
Borrowings, non-current (USD) — — — 0.00 278,190 — — — — —
Lease liabilities (USD) — — 0.00 83,926 85,745 209,412 105,782 106,891 57,170 368,259
Cash and deposits (USD) 3.64M 7.81M 8M 3.78M 1.2M 7.85M 5.96M 2.45M 3.79M 8.7M
Intangible assets (USD) — 3.91M 4.16M 4.13M 9.73M 8.7M 10.7M 8.81M 6.69M 2.06M
Right-of-use assets (USD) — — 0.00 — 83,928 209,411 116,992 106,890 57,170 285,827
Net debt (borrowings + leases - cash) (USD) — — — -3.69M -836,065 — — — — —
Cash flow detail
Operating cash flow (USD) -8.41M -6.47M -10.8M -8.15M -7.32M -10.9M -10.4M -9.56M 8.56M -9.96M
Purchases of property, plant and equipment (USD) 0.00 -36,999 -20,000 0.00 -20,077 -63,865 0.00 0.00 -6,256 -110,789
Purchases of intangible assets (USD) — 0.00 -250,000 — — — — — — —
Change in receivables (cash effect) (USD) — — — — — — — 0.00 -601,197 -921,573
Change in payables (cash effect) (USD) 712,795 -706,039 -642,435 146,636 136,697 -310,665 782,463 -808,016 226,119 1.12M
Income taxes paid (cash effect) (USD) — — — — — — — — — -2.42M
Share-based compensation (USD) 510,995 870,308 875,287 852,230 723,856 842,475 462,450 754,944 656,593 900,236
Operating cash flow before change in receivables (USD) — — — — — — — -9.56M 9.16M -9.04M
Free cash flow (OCF - PPE - intangibles) (USD) -8.41M -6.51M -11.1M -8.15M -7.34M -11M -10.4M -9.56M 8.55M -10.1M
Income detail
Research and development expense (USD) 8.42M 10.3M 8.06M 5.39M 3.57M 5.35M 3.45M 4.03M 7.84M 10.8M
↳ 5y CAGR +51.5% +59.0% +5.6% -8.7% -19.7% -12.9% +7.8% +24.8%
Total comprehensive income (USD) -13.3M -13.2M -10.8M -7.09M -8.23M -16.5M -13.7M -12.5M 3.5M -10.8M
Comprehensive income to owners (USD) -13.3M — — — — — — — — —
Reported Mar 2, 2018 Mar 1, 2019 May 8, 2019 Mar 25, 2021 May 12, 2021 Apr 15, 2022 Mar 23, 2023 Mar 25, 2025 Mar 25, 2025 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

SAN DIEGO, California — November 12, 2026 — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today reported financial results for the third quarter ended September 30, 2026, and provided a business update highlighted by the in-licensing of KIO-401, a late-stage, oral neuroprotective calpain inhibitor. The addition transforms Kiora’s development pipeline, bringing an asset supported by existing Phase 2 and Phase 3 studies conducted in Japan. Kiora is planning a multinational registration clinical trial in patients who have experienced a Central Retinal Artery Occlusion (CRAO).

Third Quarter 2026 and Recent Highlights

•Acquired late-stage lead asset: In-licensed exclusive development and commercialization rights, outside of Asia, to KIO-401 (mitucapistat) from Senju Pharmaceutical Co., Ltd., an oral calpain inhibitor supported by Phase 2 and Phase 3 clinical data from Japan.

•KIO-401 FDA engagement underway: Submitted a Type B pre-IND FDA meeting request and supporting materials to begin discussions regarding the investigational new drug application (IND) pathway, trial design and approvable endpoints for KIO-401.

October 29, 2026 7:00 am EDT Download as PDF

  • The oral small-molecule calpain inhibitor demonstrated meaningful visual acuity improvement in Phase 2 and Phase 3 CRAO studies conducted in Japan compared to controls.
  • No therapeutics exist today to treat patients that experience CRAO vision loss.
  • Kiora plans to advance KIO-401 (mitucapistat) into a multinational Phase 3 registration trial in CRAO, with initiation targeted for 2027.
  • Company also plans to evaluate KIO-401 in a Phase 2b clinical trial in non-arteritic anterior ischemic optic neuropathy ("NAION").

San Diego, California--(Newsfile Corp. - October 29, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has obtained exclusive development and commercialization rights, outside Asia, to KIO-401, a late-stage neuroprotective, oral small-molecule calpain inhibitor, from Senju Pharmaceutical Co., Ltd. ("Senju"). KIO-401 is being developed as a potential treatment for central retinal artery occlusion ("CRAO"), a rare, acute ischemic retinal disease described as "stroke of the eye" that can result in severe, permanent vision loss and for which there are currently no approved therapies.

A presentation reviewing KIO-401, its clinical data and Kiora's planned development program is available in the Investors section of the Company's website at ir.kiorapharma.com .

Senju has completed both Phase 2 and Phase 3 clinical studies of KIO-401 in patients with CRAO in Japan, providing an established clinical foundation for Kiora's planned multinational Phase 3 registration program. The Company is targeting initiation of the study in 2027 and also plans to expand development of KIO-401 into a Phase 2b clinical trial in patients with NAION, another rare, acute, ischemic, ophthalmic disease with no approved treatment.

"KIO-401 addresses a significant unmet need for patients with CRAO and NAION, two rare, acute ophthalmic diseases that result in permanent vision loss and have no approved therapies today," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "We have an established relationship with Senju through our KIO-301 partnership, which facilitated our partnership on KIO-401. After reviewing results from Senju's previous work, we identified KIO-401 as a compelling late-stage asset. We now plan to build on those findings with a larger, adequately powered multinational Phase 3 trial designed to more definitively evaluate its clinical benefit. We believe KIO-401 has the potential to meaningfully improve patient outcomes and achieve significant commercial value in the U.S., Europe and other regions."

KIO-401 : Late-Stage Program for Acute Ischemic Retinal Disease

KIO-401 (mitucapistat), designated by Senju as SJP-0008 in Japan and Asia, is a neuroprotective, oral small molecule designed to inhibit activated calpain, a calcium-dependent protease implicated in cellular injury following ischemia. CRAO is an acute retinal ischemic event caused by interruption of blood flow to the retina. NAION is caused by reduced blood flow to the optic nerve. Both conditions can trigger cellular injury through oxygen deprivation, increased intracellular calcium accumulation and excessive calpain activation. By inhibiting activated calpain, KIO-401 is intended to reduce downstream cellular damage and preserve visual function following ischemic injury.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/8481/321503_b3b0375694a08aac_001.jpg

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8481/321503_b3b0375694a08aac_001full.jpg

Cannot view this image? Visit: https://images.newsfilecorp.com/files/8481/321503_b3b0375694a08aac_002.jpg

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8481/321503_b3b0375694a08aac_002full.jpg

In the randomized Phase 2a study in Japan conducted by Senju and its partners, KIO-401 demonstrated a statistically significant improvement from baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity compared with a prospective, observational registry (p=0.0398). Senju subsequently completed a randomized, double-masked Phase 3 study in Japan, which demonstrated improvement in best-corrected visual acuity (BCVA), including a statistically significant improvement among patients who were legally blind at baseline according to World Health Organization criteria (p=0.0195).

"CRAO remains an under-recognized medical emergency, and even when diagnosed, there is no approved therapy specifically shown to preserve vision," said Brian Mac Grory, MB BCh BAO, MRCP, Associate Professor of Neurology and Ophthalmology at Duke University School of Medicine and Chair of the writing group for the American Heart Association scientific statement on CRAO. "An effective oral treatment could galvanize systems of care for acute CRAO recognition and management and expand treatment access to patients in regional and community hospitals. The reported clinical trial outcomes are the first encouraging results for a neuroprotective drug for CRAO and strongly support further evaluation of KIO-401."

Planned Clinical Development in CRAO and NAION

Kiora intends to build upon the clinical experience generated by Senju in Japan through a US-focused, multinational Phase 3 registration trial in CRAO. The Company is targeting initiation in 2027, subject to funding and regulatory alignment. The planned randomized, double-masked, controlled trial will evaluate the efficacy and safety of KIO-401 in patients with acute CRAO, with visual function outcomes expected to play a central role in the assessment of treatment benefit. The final study design, including enrollment criteria, primary endpoint and sample size, estimated to be more than 100 patients, will be determined following discussions with regulatory authorities.

"The clinical results generated in Japan support continued global development of this compound as a potential treatment for acute retinal ischemia," said Shuhei Yoshida, President & CEO of Senju Pharmaceutical. "Kiora brings retinal drug development expertise and a focused strategy for advancing the program outside Asia. Combining Senju's expertise in Japan and broader Asia with Kiora's leadership in global development, we view Kiora as a strong partner to lead development in the United States, Europe and other ex-Asia markets, with a shared goal of bringing a new treatment option to patients suffering from these ischemic insults."

In parallel, Kiora plans to advance KIO-401 into Phase 2b clinical development for NAION, an acute ischemic optic neuropathy that can cause substantial and permanent vision loss. The Company believes the shared involvement of ischemia-related cellular injury and calpain activation in CRAO and NAION provides a scientific rationale for evaluating KIO-401 in both indications. Initiation of the NAION study is targeted for 2028, subject to funding and regulatory considerations.

Kiora also intends to evaluate opportunities to expand the KIO-401 platform into additional ophthalmic indications in which calpain-mediated cellular injury may contribute to disease progression, including glaucoma. These potential indications would require further preclinical and clinical evaluation.

License Agreement with Senju Pharmaceutical

Under the terms of the agreement, Kiora has obtained exclusive rights to develop and commercialize KIO-401 outside Asia, while Senju retains rights within Asia. The agreement builds on an existing relationship between the companies involving KIO-301, Kiora's photoswitch therapy in development for advanced retinitis pigmentosa.

Under the license agreement, Kiora will make an upfront payment of $3.5 million, followed by a one-time milestone payment in the low teen millions upon technology transfer expected in 2027, a portion of which may be credited against future milestone obligations. Senju is also eligible to receive additional payments upon achievement of specified regulatory and commercial milestones, as well as single-digit royalties on applicable net sales outside Asia.

Financing and Clinical Development Strategy

Kiora is evaluating financing alternatives to fund advanced KIO-401 development in CRAO and NAION.

"Our priority is to secure capital to advance KIO-401 through late-stage development while leveraging our existing clinical infrastructure," said Melissa Tosca, CPA, Chief Financial Officer of Kiora. "We will prioritize KIO-401 and partnered KIO-301 while pursuing out-licensing opportunities for KIO-104 following discontinuation of its development."

As KIO-301's Phase 2 ABACUS-2 trial completes enrollment, Kiora expects to transition clinical resources to KIO-401's Phase 3 CRAO program. KIO-301 partner Théa Open Innovation reimburses R&D expenses and holds commercialization rights outside Asia. Kiora is eligible for up to $285 million in additional milestones and tiered royalties reaching the low 20% range. Senju Pharmaceutical holds an option for rights to KIO-301 in key Asian markets.

As Kiora prioritizes investment in KIO-401 and completes the ABACUS-2 trial, the Company made the decision to discontinue research and development of KIO-104. This decision is part of Kiora's portfolio optimization strategy and reflects the Company's current priorities. Kiora will report data from enrolled patients in the KLARITY clinical trial and consider partnering and out-licensing opportunities for the asset.

KO Law PC served as legal counsel to Kiora in connection with the KIO-401 licensing transaction.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a late-stage retinal therapeutics company developing small-molecule therapies targeting differentiated biological pathways implicated in vision-threatening diseases.

KIO-401 is an oral, neuroprotective calpain inhibitor in development for central retinal artery occlusion (CRAO) and non-arteritic anterior ischemic optic neuropathy (NAION), two rare, acute ischemic ophthalmic diseases with no approved pharmacologic treatments. Kiora is planning a multinational Phase 3 registration trial in CRAO and a Phase 2b clinical trial in NAION. The KIO-401 platform also has potential applications in additional ophthalmic indications, including glaucoma, where calpain-mediated injury may contribute to disease progression.

KIO-301 is a partnered Phase 2 photoswitch therapy for advanced retinitis pigmentosa. KIO-104, a DHODH inhibitor previously evaluated in the KLARITY clinical trial for retinal inflammation and fibrosis, is available for partnering or out-licensing.

•No therapeutics exist today to treat patients that experience CRAO vision loss.

•Kiora plans to advance KIO-401 (mitucapistat) into a multinational Phase 3 registration trial in CRAO, with initiation targeted for 2027.

•Company also plans to evaluate KIO-401 in a Phase 2b clinical trial in non-arteritic anterior ischemic optic neuropathy (“NAION”).

SAN DIEGO, October 29, 2026 — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced that it has obtained exclusive development and commercialization rights, outside Asia, to KIO-401, a late-stage neuroprotective, oral small-molecule calpain inhibitor, from Senju Pharmaceutical Co., Ltd. (“Senju”). KIO-401 is being developed as a potential treatment for central retinal artery occlusion (“CRAO”), a rare, acute ischemic retinal disease described as “stroke of the eye” that can result in severe, permanent vision loss and for which there are currently no approved therapies.

A presentation reviewing KIO-401, its clinical data and Kiora’s planned development program is available in the Investors section of the Company’s website at ir.kiorapharma.com.

Prompts

Kiora Pharmaceuticals, Inc. (ticker KPRX), listed in United States.

Company History

Date Change Detail
Nov 8, 2021 Renamed EYEGATE PHARMACEUTICALS INC → KIORA PHARMACEUTICALS INC

ETFs Holding Kiora Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
DXUV 0.00% 3,923 $ 5,217.59 Nov 12, 2026
DFSU 0.00% 1,230 $ 1,635.90 Nov 12, 2026
DFAC 0.00% 3,510 $ 4,668.30 Nov 12, 2026
DCOR 0.00% 1,574 $ 2,093.42 Nov 12, 2026